The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy-Reference-Cited by-同舟云学术

The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy

Published:2017-04-18 Issue:11 Volume:47 Page:1361-1371
ISSN:0941-1291
Container-title:Surgery Today
language:en
Short-container-title:Surg Today

Author:

Yamada Daisaku,Eguchi Hidetoshi,Asaoka Tadafumi,Tomihara Hideo,Noda Takehiro,Wada Hiroshi,Kawamoto Koichi,Gotoh Kunihito,Takeda Yutaka,Tanemura Masahiro,Mori Masaki,Doki Yuichiro

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Surgery

Link

http://link.springer.com/article/10.1007/s00595-017-1522-x/fulltext.html

Reference29 articles.

1. He J, Edil BH, Cameron JL, Schulick RD, Hruban RH, Herman JM, et al. Young patients undergoing resection of pancreatic cancer fare better than their older counterparts. J Gastrointest Surg. 2013;17(2):339–44.

2. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.

3. Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP, et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(11):1095–103.

4. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101(6):908–15.

5. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of 1-Kestose Supplementation in Patients with Pancreatic Ductal Adenocarcinoma: A Randomized Controlled Pilot Study;Nutrients;2024-08-29

2. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015);Annals of Surgical Oncology;2024-03-28

3. C-Reactive Protein-to-Albumin Ratio to Predict Tolerability of S-1 as an Adjuvant Chemotherapy in Pancreatic Cancer;Cancers;2024-02-25

4. Association of Pre-operative Geriatric Nutritional Risk Index With Complete Adjuvant Chemotherapy and Prognosis Post-pancreatectomy;Anticancer Research;2023-12-30

5. Clinical Impact of Nutrition and Inflammation Assessment Tools in Pancreatic Cancer Treatment;Anticancer Research;2023-08-30